NCT03879291 (GASSP) is a clinical trial of pinpointIQ in COPD, sponsored by Karen Larimer.

Who is sponsoring NCT03879291?

NCT03879291 is sponsored by Karen Larimer.

What drugs are being tested in NCT03879291?

Interventions in NCT03879291: pinpointIQ.

What condition does NCT03879291 study?

NCT03879291 studies COPD, Pulmonary Rehabilitation.

Is NCT03879291 still recruiting?

NCT03879291 is currently terminated. Last updated 16 March 2020.

Last reviewed 2020-03-16 · How we verify

NCT03879291: GASSP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Assessment of Utility of accelerateIQ in the Care of Patients Participating in a Pulmonary Rehabilitation Program

Terminated Last updated 16 March 2020

What this trial tests

trial testing pinpointIQ in COPD in 5 participants. Terminated before completion.

Timeline

9 January 2019

Primary endpoint
30 December 2019

30 December 2019

Quick facts

Lead sponsor	Karen Larimer
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	5
Start date	9 January 2019
Primary completion	30 December 2019
Estimated completion	30 December 2019
Sites	1 location across United States

Drugs / interventions tested

pinpointIQ

Conditions studied

COPD — all drugs for COPD →
Pulmonary Rehabilitation — all drugs for Pulmonary Rehabilitation →

Sponsor

Karen Larimer

Who can join

40 and older, any sex, with COPD or Pulmonary Rehabilitation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The proposed study seeks to assess the performance of continuous biosensor data and machine learning analytics in assessment of health patient status in a pulmonary rehabilitation program. It is hypothesized that using continuous physiologic biosensor data and machine learning analytics to detect changes in physiology may play a role in managing patients in the pulmonary rehabilitation setting.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for COPD

Currently open trials in the same condition.

NCT07344649 — Turkish Validation of the Nijmegen Questionnaire in COPD · recruiting
NCT07524023 — Emotional-distress-based Integrated Care Programme in Patients With Stable COPD · NA · recruiting
NCT07460154 — Structured Review: To Optimise Management and Prevent Harm in COPD · NA · recruiting
NCT07462221 — Effect of Telenursing on Oral Health · NA · recruiting
NCT07051707 — Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03879291 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Karen Larimer
Last refreshed: 16 March 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03879291.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing